Desang diabetes magazine diabetes news


Abbott and Bigfoot Biomedical have

entered into an agreement to develop

and commercialize diabetes management

systems, integrating Abbott's FreeStyle

Libre glucose sensing technology with

Bigfoot's insulin delivery solutions. Under

the agreement, Abbott will supply glucose

measurement sensors for all of Bigfoot's

insulin delivery systems in the U.S. as the

exclusive sensors for those systems. Bigfoot

will develop and commercialize multiple

systems using Abbott's FreeStyle Libre


sensor technology- including systems

designed to perform auto-titration for

Bigfoot's connected insulin injection

devices - as well as automated insulin

delivery using Bigfoot's insulin infusion

platform. Bigfoot currently has both

injection and infusion pump-based

insulin delivery systems in development.

The company expects to kickstart a trial

incorporating FreeStyle Libre technology

in 2018 at clinical research sites across

the country.


Our Path is based on the principles of third

wave Cognitive Behavioural Therapy (CBT).

One of the biggest problems with getting

people to change their lifestyle habits is

overcoming moments of self sabotage

or a perceived a failure in their efforts.

Acceptance and Commitment Therapy is

the idea that you do not try and change

someone's thoughts and rather encourage

them to accept they feel that way and move

towards a personally set goal. Our Path

asks patients on the program to list a set of

values at the start of the program - "I want

to be healthy for my kids" for instance -

and guides them to behave in a way that is

aligned to those values.

Founders Chris Edson and Mike

Gibbs have announced a partnership with

pharmaceuticals company Roche in the

UK, with a target of putting 750,000 people

through the program over the next five

years. This is where the savings for the NHS

comes in. "You can quantify it really easily,"

says Edson. Based off guidelines from the

National Institute for Clinical Excellence that

say three kilograms of sustained weight-loss

is cost effective if the treatment costs

£1,000 or less, Edson says Our Path will

cost the NHS just £300 over a person's

entire lifetime. The £700 difference for

each patient through the program until

2020 will save the NHS £525 million."

Now they want to expand within

the NHS. As well as being privately

available, Our Path is prescribed as

a Type 2 Diabetes measure in small

pockets of the NHS across the UK.

The slow pace comes from NHS

regulations, approvals, trials, data

security, and evidence required to

get that first commission. Edson isn't

deterred from making changes to a

system that is entrenched in old habits.

He says, "What we trying to do is

change how people's brains work after

they've spent 30 years making these

same food choices."

The plan is to roll out the programme

to 750,000 people in the UK in

partnership with Roche Diabetes Care

and save the NHS half a billion pounds.

Dexcom's 'Subscribe and Save' is

a new deal for existing customers,

providing savings to try to make

CGM more accessible. For more

details call 0800 031 5761 (UK) or

1800 827 602 (ROI).

Eli Lilly and Co. are acquiring Glycostasis,

Inc., a startup aiming to create 'smart

insulin.' Seattle-based Glycostasis,

founded by CEO Dr. John Mulligan,

was incubated by Pacific Northwest

Diabetes Research Institute (PNDRI),

and later attracted financing led by Karl

Handelsman. Lilly, a leader in insulin in

both the research and market sides,

is looking to develop the Glycostasis

technology further.

'Smart insulin' consists of a molecule

that attaches to insulin and only releases

it when blood glucose levels rise past

a certain level. This would allow insulin

in people with diabetes to more closely

mimic how the molecule is controlled in

non-diabetics. The response of the drug is

rapid and proportionate to glucose levels,

potentially doing away with glucosemonitoring

and insulin injections. By

lowering insulin levels as blood glucose

levels decrease, it could also protect

patients from hypos.



Get 20% off Fitlegs socks!

Use code des001 at checkout

Click the pic to visit website DEXCOM offer


  1. Desang diabetes magazine diabetes information
  2. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Omnipod insulin pump uk
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes kitbags
  7. Desang diabetes magazine diabetes news
  8. Diabetes technology as body art from Harvard
  9. Dexcom CGM, continuous glucose monitoring
  10. International Diabetes Federation World Diabetes Day 2017
  11. International Diabetes Federation World Diabetes Day 2017, Ascensia, Dexcom, Sanofi every1matters
  12. Accu-Chek Mobile blood glucose system
  13. Accu-Chek Mobile blood glucose system
  14. Medtronic's My Pump Choice hub
  15. Ascensia type 2 diabetes digital challenge
  16. Page 0016
  17. Diabetes food news
  18. Brindisa Spanish foods
  19. Brindisa Spanish foods, Nife is Life Italian foods, Steenbergs spices
  20. Craved craft British food and Flaming Licks fiery foods
  21. Ascensia Contour Diabetes blood test meters
  22. Bloom gin, honeybee gin, Luscombe drinks, Lyme bay wines
  23. Demuth's cookery school, Bateaux Windsor
  24. Diabetes UK, mental health for people with diabetes
  25. Diabetes UK, mental health for people with diabetes
  26. Neuropad diabetes footcare
  27. Medtronic i-Port Advance insulin injecting aid
  28. Fleur Brown, Beat Chronic Diseases, the nutrition solution
  29. Fitlegs diabetic socks
  30. Making Carbs Count swedes
  31. Making Carbs Count swedes, think vegetables
  32. Accu-Chek Insight insulin pump
  33. Accu-Chek Insight insuiln pump
  34. Free diabetes magazine, living with diabetes, the diabetic diet, carb counting

Related Issues